Prediction: Stocks That Will Outperform Summit in One Year
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
88 articles
This 6.5%-Yielding Dividend Payer Finds Fresh Ground
A high-yielding dividend payer is drawing attention as volatility grips markets. The company blends dependable income...
Insmed Reveals Japan Patient Surpasses U.S. Market
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...
MaxCyte (MXCT) 2025 Earnings Outlook for Investors
MaxCyte's 2025 earnings journey hinges on platform momentum, partnerships, and cash discipline. This guide breaks dow...
Dafna Capital Trims IShares ETF: Biotech Portfolio Moves
A major move by a prominent asset manager reveals how large portfolios tweak biotech bets. Learn what the trim means ...
Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Electrocore (ECOR) 2025 Earnings: Key Takeaways for Investors
Electrocore (ECOR) is navigating a pivotal year. This article dives into the 2025 earnings landscape, unpacking reven...
Could Data From Million Species Spark New Cures for Markets
A venture-backed biotech startup unveils a plan to collect genomic data from 100 million species to fuel AI drug disc...
Lp(a) Test and Other Things Investors Should Watch Now
New heart health guidelines urge Lp(a) testing for at-risk adults, sending demand for diagnostics higher. This report...
The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...